Table 1.

HNC survivors’ demographic and clinical characteristics (n=20).

	Statistic
Age, years; M (SD)	60.6 (9.0)
Male; n (%)	15 (75)
White; n (%)	18 (90)
Non-Hispanic; n (%)	20 (100)
Married; n (%)	13 (65)
College graduate; n (%)	11 (55)
Employed full-time; n (%)	9 (45)
Annual household income; n (%)
<$20,000	3 (15)
$20,000–$39,999	3 (15)
$40,000–$59,999	1 (5)
$60,000–$100,000	4 (20)
>$100,000	7 (35)
Did not answer	2 (10)
Smoking history; n (%)
Previous smoker	7 (35)
Current smoker	1 (5)
Never smoker	12 (60)
Primary HNC site; n (%)
Oropharynx	14 (70)
Nasopharynx	3 (15)
Oral cavity	1 (5)
Supraglottic larynx	1 (5)
Ethmoid sinus tumor	1 (5)
HPV+; n (%)	14 (70)
Months since diagnosis; M (SD)	9.1 (8.7)
Months since treatment completion; M (SD)	5.6 (4.0)
Surgery; n (%)	2 (10)
Chemotherapy regimen; n (%)
Cisplatin	19 (95)
Carboplatin + Paclitaxel	1 (5)
Chemotherapy doses; M (SD)	5 (2)
Total dose of radiation therapy, gray; range	60–70
Interview length, minutes; M (SD)	75 (23)